Radar · Life Sciences in Gyeonggi-do
Best Life Sciences Companies in Gyeonggi-do, South Korea
The 166 best Life Sciences companies in Gyeonggi-do, South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Genexine.
By Rohit KhannaTrends & Stories
166companies tracked
$948.1Mdisclosed funding
1unicorns
44have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × GYEONGGI-DO
Our analysis of 50 Life Sciences companies
$4.0b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
40%cloud-native stacks
2025funding peak (by rounds)
2018median founding year
33median Fliar Index™
Ranked: Best Life Sciences companies in Gyeonggi-do
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Genexine Developer of immunotherapeutics for treating orphan diseases, cancers & autoimmune disorders 40Product top 14%Patents top 25%Innovation top 32%Funding top 38% All 11 signals ▾Producttop 14% Patentstop 25% Innovationtop 32% Fundingtop 38% Talenttop 38% Moattop 41% Growthtop 45% Globalbottom 45% Marketbottom 37% Fin. healthbottom 34% Techbottom 23% Product: 10 distinct product lines · Company stage: Public Patents: 357 patents matched (strict assignee match) · 113 filings since 2022 vs 151 in 2017-21 rank vs industry peers · Fliar Intelligence Index 40/100 | $233M | 99 mo ago | — | Young Sung Founder & Chairman | NginxGoogle Font APIUnpkg+6 | 357 patents Therapeutic protein engineering and antibody-based cancer immunotherapies. | — |
| 2 | D&D Pharmatech Developer of GLP-1-based therapeutics for metabolic disease treatment 42Patents top 19%Funding top 23%Innovation top 28%Moat top 32% All 9 signals ▾Patentstop 19% Fundingtop 23% Innovationtop 28% Moattop 32% Talentbottom 49% Globalbottom 42% Marketbottom 39% Fin. healthbottom 39% Techbottom 31% Patents: 92 patents matched (strict assignee match) · 62 filings since 2022 vs 27 in 2017-21 Funding: Raised $205M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $205M | 12 mo ago | 16 | Seulki Lee Founder | PHPGSAPApache HTTP Server+9 | 92 patents Peptide bioconjugates with biotin/fatty acid for oral drug delivery | — |
| 3 | CHA Biotech Developer of stem cell therapeutics 40Funding top 23%News top 31%Partners top 32%Moat top 38% All 11 signals ▾Fundingtop 23% Newstop 31% Partnerstop 32% Moattop 38% Growthtop 42% Patentstop 43% Talentbottom 49% Innovationbottom 46% Techbottom 43% Marketbottom 36% Globalbottom 35% Funding: Raised $67.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) News: 5 BI events in 12 mo (of 12 tracked, 5 types) · +25% YoY rank vs industry peers · Fliar Intelligence Index 40/100 | $68M | 5 mo ago | — | Sang Oh CEO | WordPressMySQLPHP+11 | 74 patents Umbilical cord stem cell therapies and NK cell immunotherapies for reproductive and cancer treatments | — |
| 4 | ABL Bio Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases | $65M | 96 mo ago | 93 | Sang Hoon Lee Ceo/Founder | OpenSSLBootstrapApache HTTP Server+5 | 273 patents Bispecific therapeutic antibodies targeting tumor antigens and immune co‑stimulatory receptors | — |
| 5 | ImmuneOncia Developer of monoclonal and specific antibody for cancer treatment 11Funding top 37%Moat top 39%Market bottom 32%Global bottom 32% All 5 signals ▾Fundingtop 37% Moattop 39% Marketbottom 32% Globalbottom 32% Techbottom 23% Funding: Raised $60.5M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 11/100 | $60M | 53 mo ago | 21 | — | PHPGSAPApache HTTP Server+7 | — | — |
| 6 | Organoid Sciences Developer of regenerative medicines for multiple diseases | $39M | 53 mo ago | 70 | Jongman Yoo CEO | WordPressMySQLPHP+22 | — | — |
| 7 | IMBiologics Developer of antibody therapeutics to treat cancer and autoimmune diseases 40Moat top 32%Funding top 33%Patents top 36%Innovation top 45% All 6 signals ▾Moattop 32% Fundingtop 33% Patentstop 36% Innovationtop 45% Marketbottom 41% Globalbottom 40% Moat: Editorial + unicorn rating 4/10 · IP moat: 23 patents Funding: Raised $33.8M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $34M | 34 mo ago | 25 | — | — | 23 patents Engineered therapeutic antibodies/fusion proteins with extended half-life and bispecific immune targeting | — |
| 8 | Aprogen 🦄 Biotechnology company producing Biosimilars | $31M | 85 mo ago | 66 | — | DreamWeaverJavaUNIX+10 | 63 patents Therapeutic antibody formulations targeting TNF‑α and CD43 for inflammatory and cancer treatments | — |
| 9 | 1ST Bio Developer of therapies for treating neurodegenerative and immuno-oncology diseases 53Funding top 28%Talent top 28%Market bottom 46%Global bottom 37% All 4 signals ▾Fundingtop 28% Talenttop 28% Marketbottom 46% Globalbottom 37% Funding: Raised $22.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 53/100 | $22M | 4 mo ago | 34 | — | — | — | — |
| 10 | MediMabBio Developer of immunotherapeutics for treating cancer 29Moat top 32%Funding top 35%Talent top 38%Patents top 40% All 8 signals ▾Moattop 32% Fundingtop 35% Talenttop 38% Patentstop 40% Innovationtop 42% Globalbottom 31% Marketbottom 30% Techbottom 26% Moat: Editorial + unicorn rating 5/10 · IP moat: 28 patents Funding: Raised $17.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $18M | 7 mo ago | 19 | Hongseok Jo Co-Founder | WordPressMySQLPHP+12 | 28 patents Immune checkpoint antibodies (TIGIT, GITR) and cytokine‑fusion therapeutics for cancer immunotherapy | — |
| 11 | Advanced Protein Technologies Developer of biomaterials based on recombinant protein production technology | $17M | 55 mo ago | 11 | Chul Shin CEO | — | 65 patents Fucosylated oligosaccharide synthesis and therapeutic/functional food applications | — |
| 12 | Centenaire Biosciences Developer of antibody therapies to treat cancer and immune diseases | $16M | 50 mo ago | — | Yang Cheol CEO | ZURB FoundationNginxCloudflare+23 | 14 patents Engineered multi‑Fc antibody fusion proteins for enhanced therapeutic binding and effector functions. | 2 launchs · 1 partnership |
| 13 | MedPacto Company developing ALK-5 kinase inhibitors for treating solid tumors and multiple myeloma | $16M | 65 mo ago | 62 | — | PHPGSAPNginx+6 | 107 patents Targeted antibody therapeutics and diagnostics for oncology and metabolic liver disease | — |
| 14 | NOVOREX Developer of drugs for the treatment of cancer and central nervous diseases 32Funding top 33%AI top 45%Moat top 45%Patents top 50% All 8 signals ▾Fundingtop 33% AItop 45% Moattop 45% Patentstop 50% Talentbottom 45% Innovationbottom 38% Globalbottom 36% Marketbottom 34% Funding: Raised $15.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 32/100 | $15M | 1 mo ago | 20 | Woosung Son CEO | — | 4 patents Small‑molecule inhibitors of LRRK2 kinase and YEATS epigenetic reader domains | — |
| 15 | MetaFines Developer of anticancer drugs using cancer metabolism | $15M | 49 mo ago | 15 | Bae Cheol-min CEO | — | 15 patents Metal-chelate anticancer drugs and cachexia/muscle‑loss therapeutic formulations. | — |
| 16 | Bertis Developer of AI-based diagnostic platform for cancer and cardiac diseases | $13M | 60 mo ago | 46 | Inhoi Koo Co-Founder | GnuboardMySQLPHP+15 | 81 patents Cancer biomarker detection using advanced mass spectrometry and liquid chromatography methods | — |
| 17 | Amyloid Solution Provider of therapeutics solution for treating Alzheimer’s disease | $13M | 86 mo ago | 25 | Jintae Chang CEO | — | 46 patents Glycine transporter modulators and amyloid‑beta detection compounds for neurodegenerative disease therapy | — |
| 18 | QuadMedicine Provider of patch for vaccine delivery | $12M | 49 mo ago | 49 | Seung-Ki Baek CEO | jQueryGoogle WorkspaceGoDaddy+1 | 38 patents Transdermal microneedle patches for combined drug delivery, thermal therapy, and fluid sensing | — |
| 19 | Speclipse Provider of molecular spectroscopy systems for early-stage skin cancer detection | $11M | 58 mo ago | 12 | — | GnuboardMySQLPHP+11 | 124 patents AI-driven skin cancer imaging diagnostics and point‑of‑care analyte measurement devices | — |
| 20 | MBD Biotech Provider of drug efficacy and toxicity testing services | $10M | — | 30 | Bo Ku CEO | — | — | — |
| 21 | Bridge Biotherapeutics Developer of small molecule based therapeutics for the treatment of various diseases | $10M | 107 mo ago | 6 | James Jungkue Lee Founder & CEO | PHPNginxCloudflare+10 | 36 patents Small‑molecule autotaxin inhibitors and PROTACs for targeted protein degradation therapies. | — |
| 22 | Novelty Nobility Developer of therapeutics for eye and cancer diseases | $8M | 76 mo ago | 33 | Sang Park Founder & CEO | — | 55 patents Therapeutic antibodies and ADCs targeting c‑Kit, CDCP1, VEGF, HIF‑1α for cancer and mast‑cell diseases | — |
| 23 | EXOSYSTEMS Developer of a wearable medical device used for rehabilitation | $4M | 55 mo ago | 19 | Hooman Lee Founder & Co-CEO | — | 30 patents Patents concentrated in health & consumer products | — |
| 24 | AbTis Provider of technology for antibody-drug conjugation | $4M | 96 mo ago | 24 | Sang Jeon Chung Founder & CEO | — | 65 patents Site-specific antibody‑drug conjugate engineering and Fc‑binding linker technologies | — |
| 25 | Kalos Medical Developer of medical devices for the treatment of hypertension & other chronic diseases | $4M | 35 mo ago | — | Chul Kim CEO | — | 35 patents Medical catheters for nerve denervation and targeted analgesic block delivery | — |
| 26 | Genome & Company Developer of microbiome-based immuno-oncology drugs | $3M | 73 mo ago | 108 | Jisoo Pae Co-Founder & CEO | — | 252 patents Patents concentrated in computing, sensing & instrumentation | — |
| 27 | ichrogene Provider of DNA data upload and analysis for genetic insights | $944K | 77 mo ago | — | Youngah Shin Founder & CEO | — | 10 patents Pharmacogenomic risk prediction and personalized medicine platforms for type 2 diabetes | — |
| 28 | Posture 360 Provider of body aligning device | $700K | — | — | William Choi Founder & CEO | — | 2 patents Protective wearable gear for spinal support integrated into backpacks and footwear. | — |
Top 12 Life Sciences companies in Gyeonggi-do
#1
Public · Seongnam-si, Gyeonggi-do · founded 2000$67.8Mraised▾
Public · Seongnam-si, Gyeonggi-do · founded 2000
Developer of stem cell therapeutics. The company's pluripotent stem cells therapeutics include hESC-RPE (embryonic-derived RPE cells) and SCNT-RPE (somatic cell replication RPE cells) used to treat Stargardt disease and atrophic age-related macular degeneration. The company's adult stem cells therapeutic includes PLX-PAD (placental mesenchymal-like cells) for Intermittent Lameness and Severe limb ischemia, eCASs (enhanced umbilical cord stem cells) for acute stroke and degenerative disc disease, fetal–NPC (Nerve Progenitor Cell) for Parkinson's disease, and adipose-derived mesenchymal stem cells for degenerative lumbar vertebra. The company also aims to develop immune cell therapy to treat Relapsed glioblastoma.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 23%News
top 31%Partners
top 32%Moat
top 38%Growth
top 42%Patents
top 43%Funding: Raised $67.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Post IPO (Jan 2026)
News: 5 BI events in 12 mo (of 12 tracked, 5 types) · +25% YoY · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo
Partners: 2 partnership announcements in 12 mo (2 in 24 mo) · Marquee-customer mentions: top 30% of tracked companies
Funding rounds
- Jan 2026Post IPO$67.8M
Founders & team
Investors
Hanwha Life, Hanwha General Insurance, Synergy IB investment, Korea Investment Private Equity, GNTech Venture Capital
Tech stack
CdnjsCloudflareGoogle AnalyticsGoogle Tag ManagerGsapIis
#2
Series B · Seongnam-si, Gyeonggi-do · founded 2020 · 20 employees$15Mraised▾
Series B · Seongnam-si, Gyeonggi-do · founded 2020 · 20 employees
Developer of drugs for the treatment of cancer and central nervous diseases. The company develops GPCR-targeted small-molecule drugs using artificial intelligence to treat neurological disorders, cognitive function, and cancer.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 33%AI
top 45%Moat
top 45%Patents
top 50%Talent
bottom 45%Innovation
bottom 38%Funding: Raised $15.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (Apr 2026)
AI: Product described with: artificial intelligence
Moat: Editorial + unicorn rating 4/10 · IP moat: 4 patents
Funding rounds
- Apr 2026Series B$15M
Founders & team
Investors
KB Investment, UTC Investment, Korean Development Bank, SBI Investment, Hyundai Venture Investment, K&Investment Partners
#3
Public · Seongnam-si, Gyeonggi-do · founded 2014 · 16 employees$204.7Mraised▾
Public · Seongnam-si, Gyeonggi-do · founded 2014 · 16 employees
Developer of GLP-1-based therapeutics for metabolic disease treatment. It focuses on building on a robust foundation of proprietary peptide research and strategic collaborations. D&D Pharmatech is advancing a diverse pipeline of therapeutics for metabolic, fibrotic, and neurodegenerative diseases. The global biotech company’s umbrella structure comprises three U.S. subsidiaries, including Neuraly Inc, its clinical research arm responsible for conducting clinical trials for the company’s pipeline, including its dual agonist (GLP-1/glucagon) for metabolic dysfunction-associated steatohepatitis (MASH).
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Patents
top 19%Funding
top 23%Innovation
top 28%Moat
top 32%Talent
bottom 49%Global
bottom 42%Patents: 92 patents matched (strict assignee match) · 62 filings since 2022 vs 27 in 2017-21 · Latest publication 2026
Funding: Raised $205M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) · Last round Post IPO (Jun 2025)
Innovation: 92 patents (top 31% of patent-holders) · 62 filings since 2022 vs 27 in 2017-21
Funding rounds
- Jun 2025Post IPO$10.8M
- Oct 2021Series C$51M
- Feb 2020Grant (prize money)—
- Aug 2019Series B$137.1M
Founders & team
Investors
Alzheimer's Drug Discovery, Praxis Capital, DS, Kudos Ventures, Korea Investment Holdings, Smile Gate Investment
Tech stack
Apache Http ServerCdnjsCloudflareGsapHstsJquery
#4
Series D · Seongnam-si, Gyeonggi-do · founded 2016 · 34 employees$22Mraised▾
Series D · Seongnam-si, Gyeonggi-do · founded 2016 · 34 employees
1ST Bio is developing therapies for treating neurodegenerative and immuno-oncological diseases. The lead candidate of the company, 1ST 102 is a tyrosine kinase enzyme inhibitor. It's in the preclinical phase which is used for treating Parkinson's Disease. Other candidates like 1ST-101 and 1ST-103 are in the discovery stage.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 28%Talent
top 28%Market
bottom 46%Global
bottom 37%Funding: Raised $22.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series D (Jan 2026)
Talent: Analyst team rating 4/5
Market: 34 employees (top 46% of Life Sciences)
Funding rounds
- Jan 2026Series D$22M
Investors
Smile Gate Investment, LigaChemBio, Korea Investment Holdings, Anda Asset Management, Daily Partners, Mirae Asset
#5
Series B · Seongnam-si, Gyeonggi-do · founded 2017 · 19 employees$17.8Mraised▾
Series B · Seongnam-si, Gyeonggi-do · founded 2017 · 19 employees
MediMabBio is a developer of immunotherapeutics for treating cancer. The company develops immuno-oncology drugs using its drug discovery platform with a combination of systems biology and immunological solutions to target solid tumors. The products pipeline includes immune checkpoint antibody (MMB-101) in lead optimization stage and immuno cytokine agents (MMB-201) in hit optimization stage.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Moat
top 32%Funding
top 35%Talent
top 38%Patents
top 40%Innovation
top 42%Global
bottom 31%Moat: Editorial + unicorn rating 5/10 · IP moat: 28 patents
Funding: Raised $17.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (Oct 2025)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 571 LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series B$17.8M
Founders & team
Investors
KB Investment, Smile Gate Investment, BNH INVESTMENT, Hyundai-invest.com, iM Investment Partners, Time Polio Asset Management
Tech stack
Apache Http ServerBootstrapCookieyesGoogle AnalyticsGoogle Font ApiJquery
#6
Public · Suwon-si, Gyeonggi-do · founded 2020 · 25 employees$33.8Mraised▾
Public · Suwon-si, Gyeonggi-do · founded 2020 · 25 employees
Developer of antibody therapeutics to treat cancer and autoimmune diseases. The company has developed a platform technology called ePendy that can generate antibody therapeutics for the treatment of autoimmune diseases and cancer.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Moat
top 32%Funding
top 33%Patents
top 36%Innovation
top 45%Market
bottom 41%Global
bottom 40%Moat: Editorial + unicorn rating 4/10 · IP moat: 23 patents
Funding: Raised $33.8M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series B (Jul 2023)
Patents: 23 patents matched (strict assignee match) · 23 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Funding rounds
- Jul 2023Series B$15.5M
- Aug 2021Series A$14.7M
- Jan 2021Seed$3.6M
Investors
KB Investment, Atinum Investment, Partners Investment, CJ Investment, K2 Investment Partners, Shinhan Venture Investment
#7
Public · Seongnam-si, Gyeonggi-do · founded 2002$233Mraised▾
Public · Seongnam-si, Gyeonggi-do · founded 2002
Developer of immunotherapeutics for treating orphan diseases, cancers & autoimmune disorders. The company has developed drug candidates for Growth Hormone Deficiencies, Cervical Cancers, and Anemias. Its technology is based on Fc fusion proteins and DNA Vaccines.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Product
top 14%Patents
top 25%Innovation
top 32%Funding
top 38%Talent
top 38%Moat
top 41%Product: 10 distinct product lines · Company stage: Public
Patents: 357 patents matched (strict assignee match) · 113 filings since 2022 vs 151 in 2017-21 · Latest publication 2025
Innovation: 357 patents (top 8% of patent-holders) · 113 filings since 2022 vs 151 in 2017-21 · 10 product lines
Audience (LinkedIn): 1k LinkedIn followers — 4.4% of this cohort's audience
Funding rounds
- Mar 2018Post IPO$233M
Founders & team
Investors
Aju IB Investment, InterVest, Hyundai Venture Investment, Wooshin Venture Investment, IMM Holdings, Now IB Capital
Tech stack
Fullpage.JsGoogle Font ApiJqueryNginxOpen GraphPhp
#8
Public · Seongnam-si, Gyeonggi-do · founded 2016 · 21 employees$60.5Mraised▾
Public · Seongnam-si, Gyeonggi-do · founded 2016 · 21 employees
Developer of monoclonal and specific antibody for cancer treatment. The company's lead antibody IMC-001 is currently in phase 1 of the clinical trial. The company has a pipeline of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors.
Fliar Intelligence Index™ 11how this company ranks against its industry peers
Funding
top 37%Moat
top 39%Market
bottom 32%Global
bottom 32%Tech
bottom 23%Funding: Raised $60.5M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) · Last round Series B (Jan 2022)
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Market: 21 employees · Top-50,000,000 web property
Audience (LinkedIn): 563 LinkedIn followers
Funding rounds
- Jan 2022Series B$20.5M
- Feb 2019Series A$40M
Investors
Yuhan Corporation, Premier Partners, K2 Investment Partners, BNH INVESTMENT, E&Investment, Hanyang Securities
Tech stack
Apache Http ServerCore-JsFont AwesomeGoogle Font ApiGsapIis
#9
Public · Seongnam-si, Gyeonggi-do · founded 2019 · 70 employees$39Mraised▾
Public · Seongnam-si, Gyeonggi-do · founded 2019 · 70 employees
Organoid Sciences is a developer of regenerative medicines for multiple diseases. It uses cannabinoid-based technology for the development of a regenerative medicine pipeline.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers — 3.2% of this cohort's audience
Funding rounds
- Jan 2022Series B$32.5M
- Mar 2020Series A$6.4M
Founders & team
Investors
Korea Development Bank Europe, Asan Foundation, Dongwha Pharm, Wonik Investment Partners, Time Polio Asset Management, Company K Partners
#10
Public · Seongnam-si, Gyeonggi-do · founded 2016 · 93 employees$65Mraised▾
Public · Seongnam-si, Gyeonggi-do · founded 2016 · 93 employees
ABL Bio is a Korean, clinical-stage biopharma developing immunotherapies for oncology and neurodegenerative diseases. Their first lead candidate is ABL001 a bispecific antibody targeting DII4 & VEGF and is indicated for solid tumors. The second bispecific antibody is ABL301, a BBB penetrating Bispecific antibody for targeting Alpha-Synuclein, and indicated for Parkinson's Disease and other synucleopathies. The company is developing 4 ADCs for various cancer indications (MM, AML, CLL, TNBC).
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers — 9.7% of this cohort's audience
Activity: 1 product launches · 2 partnerships (incl. Eli Lilly and Company (Lilly)) announced in 12 mo
Funding rounds
- Jun 2018Series C$65M
- 2016Seed—
Founders & team
Investors
DSC Investment, DS, QUAD, Hana Financial Group, Timefolio Capital, Alpen Route
Tech stack
Apache Http ServerBootstrapGoogle AnalyticsGoogle WorkspaceJqueryOpen Graph
#11
Series A · Suwon-si, Gyeonggi-do · founded 2021$16.4Mraised▾
Series A · Suwon-si, Gyeonggi-do · founded 2021
Developer of antibody therapies to treat cancer and immune diseases. The company focuses on developing an antibody platform based on proprietary technology to develop cancer-targeted drugs. The flagship product of the company is CTN001 a human epidermal growth factor receptor 2 (HER2)-targeting antibody, to treat HER2-low-expressing breast cancer.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 9k LinkedIn followers — 26.1% of this cohort's audience
Activity: 2 product launches · 1 partnerships announced in 12 mo
Funding rounds
- Mar 2022Series A$16.4M
Founders & team
Investors
Bionote, Sdb
Tech stack
Adobe Audience ManagerAosAppnexusClipboard.JsCloudflareCloudflare Bot Management
#12
Series B · Seongnam, Gyeonggi-do · founded 2021 · 15 employees$14.8Mraised▾
Series B · Seongnam, Gyeonggi-do · founded 2021 · 15 employees
Developer of anticancer drugs using cancer metabolism. The company's lead product 'ASCA101' is a novel pharmaceutical composition for cancer treatment that inhibits the effects of cancer cell proliferation, invasion, and metastasis. Other drug candidates include MF03 for Cancer Acidosis and MF04 for Cachexia.
Funding rounds
- Apr 2022Series B$14.8M
Founders & team
Investors
DSC Investment, BM Korea, Korea Investment Value Asset Management, Prodigy Investment, Meritz Securities, Meritz Capital
Funding & investor landscape
$948.1Mtotal disclosed funding
28companies funded
39disclosed rounds
1rounds last 90 days
Most active investors
Notable founders
Sang Oh
CEO · CHA Biotech
Woosung Son
CEO · NOVOREX
Seulki Lee
Founder · D&D Pharmatech
Hongseok Jo
Co-Founder · MediMabBio
Jennifer Kang
Co-Founder & Co-CEO · MediMabBio
Young Sung
Founder & Chairman · Genexine
Neil Warma
CEO · Genexine
Jongman Yoo
CEO · Organoid Sciences
Sang Hoon Lee
Ceo/Founder · ABL Bio
Hyunkyu Park
Co-Founder · Centenaire Biosciences
Bae Cheol-min
CEO · MetaFines
Chul Shin
CEO · Advanced Protein Technologies
Prism market signals · South Korea · country-scoped Prism corpus, 618,093 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · South Korea
How research on Biotechnology is moving in South Korea
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 885 South Korea-affiliated papers.
research sentiment over time
201120172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and softening — the enthusiastic (strongly-positive) share moved 79% → 51% across 2011–2026.
top research entities
- Ministry of Agriculture118
- Ministry of Education70
- Seoul National University53
- Yonsei University44
- Korea University36
leading researchers
Lee Joohee · Kim Junhan · Kim Sung Hee · Jang Hyunbeen · Hong Seunghee · Heebeom Koo · Pradeep Kumar · Soobin Shin
▲
Breakthroughs227 · 26%
▼ 28%→26% share
▼0.9× share momentum0 median citations89% since 2021mostly methods-led
Gene editing research is surging — Gene and Genome editing topics scaled from 1–2 to 26 and 10 papers respectively in South Korean biotech.
rising sub-themes (early→recent)
- Gene2→26
- Genome1→10
- Transcription factor1→9
- Genome editing1→6
- Transformation (genetics)1→6
Newly emergingMutant 0→12 · Antibody 0→12 · Synthetic biology 0→8
Landmark Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins · 1,853 cites
◆
Advancements409 · 46%
▲ 36%→48% share
▲1.3× share momentum0 median citations91% since 2021mostly empirical
Antimicrobial and apoptosis research is intensifying — Antimicrobial papers rose from 1 to 23, driving Advancements' field-share from 36% to 48%.
rising sub-themes (early→recent)
- Antimicrobial1→23
- Apoptosis1→12
- Cell culture2→10
- Cytotoxicity2→8
- Gene knockdown1→7
Newly emergingGene 0→34 · Microbiome 0→18 · Transcriptome 0→18
Landmark The promising future of microalgae: current status, challenges, and optimization of a sustainable and renewable industry · 1,986 cites
▼
Concerns107 · 12%
▼ 15%→12% share
▼0.8× share momentum0 median citations87% since 2021mostly reviews
Antibiotic resistance and sustainability concerns are newly consolidating — Agriculture (8) and Sustainability (6) emerged brand-new alongside rising Antibiotic resistance (1→4).
rising sub-themes (early→recent)
- Human health2→11
- Health benefits1→6
- Antibiotic resistance1→4
- Toxicity2→4
Newly emergingAgriculture 0→8 · Sustainability 0→6
Landmark Microplastic Size-Dependent Toxicity, Oxidative Stress Induction, and p-JNK and p-p38 Activation in the Monogonont Rotif · 1,181 cites
RESEARCH HOTSPOTS · South Korea
Where biotechnology is researched across South Korea
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Seoul229 · +0.44
Daejeon83 · +0.54
Jeonju71 · +0.51
Daegu57 · +0.42
Busan47 · +0.48
Gwangju30 · +0.39
Suwon25 · +0.52
Incheon18 · +0.39
Seongnam-si11 · +0.60
Ulsan10 · +0.75
PATENT SIGNAL · South Korea
Who's filing biotechnology patents in South Korea
South Korea biotechnology patent filing is accelerating — 58,964 filings from 8,000 assignees (2016–2025), led by CJ Cheiljedang, UNIV Korea RES & BUS Found, Samsung; annual filings 4052→6791.
58,964 filings8,000 assigneespeak 7106/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- CJ Cheiljedang6610
- UNIV Korea RES & BUS Found1920
- Samsung1764
- Korea Advanced INST SCI & TECH1760
- Seoul NAT UNIV R&DB Foundation1752
- Korea RES INST Of Bioscience1538
- Hanmi Pharm IND1198
- Korea RES INST Bioscience & Biot1009
Common questions
How many Life Sciences companies are there in Gyeonggi-do, South Korea?
Radar tracks 166 indexable Life Sciences companies headquartered in Gyeonggi-do, South Korea that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Gyeonggi-do, South Korea?
The Life Sciences companies in Gyeonggi-do, South Korea on this list have raised a combined $948.1M in disclosed equity funding across 28 funded companies.
Which is the highest-funded Life Sciences company in Gyeonggi-do, South Korea?
Genexine is the highest-funded Life Sciences company in Gyeonggi-do, South Korea, with $233M in disclosed equity funding.
How many Life Sciences companies in Gyeonggi-do, South Korea are funded?
28 of the 166 Life Sciences companies in Gyeonggi-do, South Korea on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Gyeonggi-do, South Korea?
1 Life Sciences company in Gyeonggi-do, South Korea on this list is valued at $1B or more.
Who are the top investors in Gyeonggi-do, South Korea Life Sciences companies?
The most active investors in Gyeonggi-do, South Korea Life Sciences companies on this list include Korea Investment Holdings, Aju IB Investment, GNTech Venture Capital, BNH INVESTMENT, DSC Investment.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.